Clopidogrel is FDA approved for the medical management of unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI), ST-segment elevation myocardial infarction (STEMI) in patients receiving fibrinolytic therapy, and for secondary prevention in recent myocardial infarction (MI), recent stroke, and peripheral arterial disease. There also a number of other FDA-approved uses. This activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of clopidogrel, pertinent for members of the interprofessional team where this agent is indicated.

**Objectives:**
- Explain the mechanism of action of clopidogrel.
- Review the indications for initiating therapy with clopidogrel.
- Describe the significant drug-drug interactions that might occur when prescribing clopidogrel.
- Outline the importance of improving care coordination among interprofessional team members to improve outcomes for patients on clopidogrel therapy.